Head to Head Review: Flora Growth (NASDAQ:FLGC) & Demant A/S (OTCMKTS:WILYY)

Flora Growth (NASDAQ:FLGC) and Demant A/S (OTCMKTS:WILYY) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Flora Growth and Demant A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flora Growth	1	0	1	0	2.00
Demant A/S	0	1	0	2	3.33

Flora Growth presently has a consensus target price of $30.00, indicating a potential upside of 349.10%. Given Flora Growth’s higher possible upside, analysts plainly believe Flora Growth is more favorable than Demant A/S.

Earnings and Valuation

This table compares Flora Growth and Demant A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Flora Growth	$57.61 million	0.12	-$15.91 million	($32.49)	-0.21
Demant A/S	$3.48 billion	2.10	$233.91 million	N/A	N/A

Demant A/S has higher revenue and earnings than Flora Growth.

Institutional and Insider Ownership

36.0% of Flora Growth shares are owned by institutional investors. 2.3% of Flora Growth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Flora Growth has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, Demant A/S has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Flora Growth and Demant A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flora Growth	-32.03%	-64.02%	-34.46%
Demant A/S	N/A	N/A	N/A

Summary

Demant A/S beats Flora Growth on 8 of the 13 factors compared between the two stocks.

About Flora Growth

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.

About Demant A/S

Demant A/S operates as a hearing healthcare and audio technology company in Europe, North America, the Asia Pacific, Asia, and internationally. It operates through two segments: Hearing Healthcare and Communications. The Hearing Healthcare segment is involved in the manufacturing, servicing, and sale of hearing aids, and diagnostic products and services. The Communications segment provides headsets and solutions for the professional call centers, office markets, and gaming markets under the EPOS brand name. The company was formerly known as William Demant Holding A/S and changed its name to Demant A/S in March 2019. Demant A/S was founded in 1904 and is headquartered in Smørum, Denmark.